Cardiovascular disease is the leading cause of death in the US population. Lipid-lowering agents prevent coronary heart disease and the occurrence of a second heart attack, and sales of lipid-lowering drugs total billions of dollars annually.
New and improved hypolipidemic agents represent one of the fastest growing segments of this market, and opportunities exist for the development of new therapeutic agents with greater efficacy and safety.
This article discusses recent advances in the development of new therapeutic hypolipidemic agents, including recently approved statins and bile acid sequestrants. Novel enzyme targets and genetic approaches are also reviewed.